APA (7th ed.) Citation

Lomeli, B. K., Galbraith, H., Schettler, J., Saviolakis, G. A., El-Amin, W., Osborn, B., . . . Janjic, N. (2019). Multiple-Ascending-Dose Phase 1 Clinical Study of the Safety, Tolerability, and Pharmacokinetics of CRS3123, a Narrow-Spectrum Agent with Minimal Disruption of Normal Gut Microbiota. Antimicrobial agents and chemotherapy, 64(1), . https://doi.org/10.1128/AAC.01395-19

Chicago Style (17th ed.) Citation

Lomeli, Barbara K., et al. "Multiple-Ascending-Dose Phase 1 Clinical Study of the Safety, Tolerability, and Pharmacokinetics of CRS3123, a Narrow-Spectrum Agent with Minimal Disruption of Normal Gut Microbiota." Antimicrobial Agents and Chemotherapy 64, no. 1 (2019). https://doi.org/10.1128/AAC.01395-19.

MLA (9th ed.) Citation

Lomeli, Barbara K., et al. "Multiple-Ascending-Dose Phase 1 Clinical Study of the Safety, Tolerability, and Pharmacokinetics of CRS3123, a Narrow-Spectrum Agent with Minimal Disruption of Normal Gut Microbiota." Antimicrobial Agents and Chemotherapy, vol. 64, no. 1, 2019, https://doi.org/10.1128/AAC.01395-19.